Orchestra BioMed Holdings (OBIO) AI Stock Analysis

• Market Cap: $132.73M
• Dividend Yield: N/A
• Average Volume (3M): 328.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.18
• Revenue Growth: 41.61%
• EPS Growth: -17.39%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 53,955,086
• 10 Day Avg. Volume: 189,223
• 30 Day Avg. Volume: 328,527
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 28.98
• Enterprise Value/Gross Profit: 31.28
• Enterprise Value/Ebitda: -1.20
• 1Y Price Target: $12.50
• Price Target Upside: 408.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 47 Neutral
• Price Target: $2.50 ▲(1.63% Upside)

Orchestra BioMed Holdings faces significant financial challenges with high leverage and ongoing losses, reflected in a low financial performance score. The technical analysis indicates a bearish trend, and the valuation is weak due to negative earnings. However, the recent strategic investment in cardiology programs provides a positive outlook, partially offsetting the financial concerns.

Positive Factors

Strategic Investment

The $70M investment reflects confidence in Orchestra BioMed's clinical progress and potential, supporting key milestones in cardiology programs.

Partnerships and Collaborations

Partnership with Medtronic enhances product development and distribution capabilities, potentially transforming care for hypertension patients.

Revenue Growth

Strong revenue growth indicates increasing market adoption of products and successful commercialization strategies.

Negative Factors

High Leverage

High leverage poses a risk to financial stability, potentially limiting financial flexibility and increasing vulnerability to economic downturns.

Profitability Challenges

Negative profit margins indicate operational inefficiencies and ongoing losses, challenging long-term sustainability and shareholder returns.

Cash Flow Concerns

Negative operating cash flow suggests cash generation issues, potentially impacting the company's ability to fund operations and growth initiatives.

Orchestra BioMed Holdings Business Overview & Revenue Model

Company Description

Orchestra BioMed Holdings (OBIO) is a biomedical innovation company specializing in the development of advanced therapeutic solutions. The company operates within the sectors of biotechnology and medical devices, focusing on addressing significant unmet medical needs. Its core products include novel therapies and devices designed to improve patient outcomes in areas such as cardiovascular disease, hypertension, and other serious health conditions.

How the Company Makes Money

Orchestra BioMed Holdings makes money primarily through the development and commercialization of its proprietary medical therapies and devices. The company's revenue model is based on partnerships and collaborations with established healthcare companies, where it licenses its technologies for further development and distribution. These partnerships often involve upfront payments, milestone payments, and royalties on sales of products developed using Orchestra BioMed's technologies. Additionally, the company may engage in direct sales of its products, once approved, to healthcare providers and institutions. Significant partnerships with leading medical device and biopharmaceutical companies contribute to its earnings by leveraging their distribution networks and regulatory expertise to bring products to market efficiently.

Orchestra BioMed Holdings Financial Statement Overview

Summary

Orchestra BioMed Holdings shows slight revenue growth but faces significant profitability challenges with a deeply negative net profit margin and high leverage, indicating financial vulnerability.

Income Statement

Orchestra BioMed Holdings has shown a slight revenue growth of 2.01% in the TTM, but the company continues to face significant profitability challenges. The gross profit margin is strong at 92.66%, indicating efficient cost management relative to revenue. However, the net profit margin is deeply negative at -23.67%, reflecting substantial losses. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies. Overall, while revenue is growing, profitability remains a significant concern.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 6.68 in the TTM, indicating heavy reliance on debt financing, which poses a risk in terms of financial stability. The return on equity is negative, reflecting ongoing losses and poor returns for shareholders. The equity ratio is not directly provided, but the high leverage suggests a low equity base relative to assets. Overall, the balance sheet indicates financial vulnerability due to high leverage and negative equity returns.

Cash Flow

Cash flow analysis shows a modest improvement in free cash flow growth at 9.64% in the TTM, but the company still faces negative operating cash flow. The operating cash flow to net income ratio is negative, indicating cash flow challenges relative to net losses. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net losses. Overall, cash flow remains a concern, though there are slight improvements in free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.94M	2.64M	2.76M	3.53M	-782.00K	5.70M
Gross Profit	2.73M	2.43M	2.57M	3.21M	-981.00K	5.56M
EBITDA	-71.11M	-64.30M	-51.22M	-32.44M	-21.62M	-18.61M
Net Income	-69.70M	-61.02M	-49.12M	-33.61M	-23.01M	-21.36M
Balance Sheet
Total Assets	42.83M	76.17M	95.21M	95.57M	13.53M	38.09M
Cash, Cash Equivalents and Short-Term Investments	33.92M	66.81M	87.59M	83.78M	10.90M	35.79M
Total Debt	1.97M	16.53M	1.69M	11.87M	5.67M	9.46M
Total Liabilities	42.53M	43.22M	27.17M	43.04M	84.76M	86.63M
Stockholders Equity	295.00K	32.96M	68.04M	52.53M	-71.23M	-48.54M
Cash Flow
Free Cash Flow	-59.70M	-50.85M	-46.20M	-29.88M	-19.70M	-26.72M
Operating Cash Flow	-59.38M	-50.56M	-46.13M	-29.29M	-19.43M	-26.18M
Investing Cash Flow	26.16M	13.09M	10.69M	-64.12M	13.02M	26.97M
Financing Cash Flow	28.26M	29.17M	46.22M	103.26M	-3.99M	10.00M

Orchestra BioMed Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OBIO, the sentiment is Negative. The current price of 2.46 is below the 20-day moving average (MA) of 2.66, below the 50-day MA of 2.80, and below the 200-day MA of 3.75, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 38.17 is Neutral, neither overbought nor oversold. The STOCH value of 12.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OBIO.

Orchestra BioMed Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NKTR	56 Neutral	971.28M	-5.86	505.02%	―	-19.56%	35.55%
LRMR	49 Neutral	349.21M	-2.61	0.00%	―	0.00%	-40.03%
OBIO	47 Neutral	$132.73M	―	-313.82%	―	41.61%	-17.39%
RAPT	39 Underperform	297.68M	-1.27	0.00%	―	0.00%	43.16%
ALDX	37 Underperform	293.49M	-5.78	0.00%	―	0.00%	-32.74%
KOD	35 Underperform	486.49M	-2.43	0.00%	―	0.00%	-0.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Orchestra BioMed Holdings Corporate Events

Orchestra BioMed Holdings Closes $40M Public Offering

On August 1, 2025, Orchestra BioMed Holdings announced the pricing of its underwritten public offering, which included 9,413,637 shares of common stock and pre-funded warrants, raising approximately $40 million. The proceeds will support the company’s atrioventricular interval modulation therapy program, the BACKBEAT study, the Virtue SAB program, and other research and development initiatives. The offering closed on August 4, 2025, and was part of a broader strategy to advance its cardiovascular care technologies.

Orchestra BioMed Secures $70M for Cardiology Programs

On July 31, 2025, Orchestra BioMed Holdings announced securing $70 million in strategic capital from Ligand Pharmaceuticals and Medtronic to advance its late-stage cardiology programs. This investment includes Ligand’s $40 million commitment and Medtronic’s $30 million, reflecting confidence in Orchestra BioMed’s clinical progress and potential. The collaboration with Medtronic has been expanded to potentially integrate AVIM therapy into leadless pacemaker technology, aiming to transform care for patients with uncontrolled hypertension. This financial backing and strategic alignment are expected to support Orchestra BioMed in achieving key milestones in its high-impact clinical programs, addressing significant unmet medical needs in global markets.

Orchestra BioMed Confirms Director Elections and Auditor

On June 24, 2025, Orchestra BioMed Holdings, Inc. held its Annual Meeting of Stockholders, where stockholders voted on two key proposals. The election of three Class II directors, Chris Cleary, Pamela Connealy, and David Pacitti, was confirmed, and the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.